NCT00125372View on ClinicalTrials.gov

Study of Tarceva and Targretin in Stage I-II Lung Cancer

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Carcinoma, Non-small-cell Lung
Interventions
DRUG

erlotinib (Tarceva) and bexarotene (Targretin)

Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy

Trial Locations (1)

03756

Norris Cotton Cancer Center, Lebanon

Sponsors
All Listed Sponsors
collaborator

Ligand Pharmaceuticals

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Dartmouth-Hitchcock Medical Center

OTHER